Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. ; info:eu-repo/semantics/published
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Sciences bio-médicales et agricoles / Aged / Antibodies / Monoclonal -- therapeutic use / Monoclonal / Humanized -- therapeutic use / Belgium / COVID-19 -- drug therapy / Cytokine Release Syndrome -- drug therapy -- virology / Female / Ferritins / Humans / Hypoxia / Interleukin-1 -- antagonists & inhibitors / Interleukin-6 -- antagonists & inhibitors / Male / Middle Aged / Oxygen / Prospective Studies / Respiratory Insufficiency -- drug therapy -- virology / SARS-CoV-2 / Treatment Outcome |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26589039 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/345120 |